TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Tenaya Therapeutics
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics announced promising interim clinical results for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy, showing improved biomarkers, reduced hypertrophy, and manageable safety profile in early-stage trials.

Insights
TNYA   positive

Presented promising early clinical trial results with positive safety and efficacy signals for TN-201 gene therapy, showing improvements in multiple disease parameters and no significant adverse events